Interchangeable Biosimilars: Faster Approval, Same Price?

Photo by Haberdoedas on Unsplash

The Common Belief

What if the fastest part of a biosimilar's journey is the regulatory review, and the slow part is everything that happens after the approval letter? That question is worth asking on September 8, 2026, because the story circulating about interchangeable biosimilars right now is a story about speed — and speed at the regulator is not the same thing as speed at the pharmacy counter.

According to Google News, which surfaced MarketScale's coverage of the subject, Wezlana is being held up as the illustration of a broader shift: the U.S. Food and Drug Administration moving faster on interchangeable biosimilars in order to widen competition and bring down the cost of expensive biologic drugs. The framing is reasonable. It is also incomplete in a way that matters for anyone budgeting a specialty prescription or holding pharmaceutical names in an investment portfolio.

Here are the underlying facts, stripped of spin. Wezlana (ustekinumab-auub) is Amgen's biosimilar version of Stelara (ustekinumab), the Johnson & Johnson biologic. The FDA approved it in late 2023 as the first interchangeable biosimilar to Stelara. Ustekinumab is an IL-12/IL-23 antagonist — in plain English, a drug that blocks two immune-signaling proteins involved in inflammation — and it is prescribed for plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. The interchangeability designation is the piece people fixate on: it means a pharmacist may substitute the biosimilar for the brand without going back to the prescriber, in states whose pharmacy laws allow it.

Where It Breaks Down

The approval date and the availability date are two entirely different events, and the distance between them is where the savings narrative gets complicated.

Wezlana cleared the FDA in late 2023. The U.S. commercial launch of Stelara biosimilars, Wezlana included, happened in 2025, following patent settlement agreements with J&J's Janssen unit. Do the arithmetic on the calendar rather than the press releases: a full year and then some separated the regulator's yes from a product a patient could actually pick up. And none of that delay was a regulatory bottleneck. It was intellectual property and contract negotiation. Accelerating the approval side of a pipeline whose true constraint sits downstream produces a faster queue, not a faster outcome.

A word on evidence tier, because this blog cares about it. The material supporting this analysis is regulatory record and trade reporting, not peer-reviewed outcomes research or audited pricing data. Attempts to verify live figures for this briefing returned errors, and no specific price, discount percentage or savings statistic could be independently confirmed as of September 8, 2026. That absence is itself informative: if you encounter a headline claiming a precise percentage that biosimilars have knocked off ustekinumab spending, trace it to a primary source — FDA's Purple Book, a company investor filing, or CMS data — before you repeat it or trade on it.

Now the fair counter-argument. A skeptic could reasonably say that interchangeability is doing genuine work, because pharmacy-level substitution operating across millions of scripts is precisely how generics collapsed small-molecule prices, and that arguing otherwise is missing the mechanism. That objection has merit. But the designation only unlocks a possibility, and that possibility is gated by three separate conditions: state pharmacy substitution law, formulary and pharmacy-benefit-manager placement, and actual supply. Fail any one and the interchangeable label changes nothing about what a household pays.

There is a second-order point the surface coverage tends to skip. The FDA and Congress have both discussed streamlining — or reconsidering entirely — the separate interchangeability designation, with agency guidance evolving to make the status easier to obtain. If a badge becomes easier to earn, its value as a differentiator falls. A company touting the first interchangeable approval in a category is describing a moat that regulators are actively filling in.

Consider the before-and-after, which no single news item lays out cleanly. Before 2025, the number of ustekinumab biosimilars a U.S. patient could obtain was zero, despite an approval already sitting on the books. After launch, the field included products from Amgen, Teva/Alvotech, Sandoz, Fresenius Kabi and Samsung Bioepis — five distinct competitive sources instead of one monopoly. That shift from one to five is the variable that historically drives price, and it has almost nothing to do with which product got the interchangeable stamp first.

Who benefits, and under what condition? A patient whose insurer moves the biosimilar to a preferred tier and whose state permits pharmacist substitution is positioned to see a real change in out-of-pocket cost. A patient whose plan keeps the originator brand in the preferred position — often because rebate economics favor the incumbent — may see no change at all, or even a worse deal if brand copay assistance was already absorbing most of the bill. Same drug class, same approval, opposite household outcome. That divergence is a plan-design question, not a science question.

A Better Frame

For most people, this means the practical question is not whether the FDA approved something interchangeable. It is what your specific plan does with it.

For readers approaching this from the market side rather than the patient side: the investable signal in biosimilars has rarely been the first approval. It is the count of launched competitors and the timing of the patent settlements that release them — information that lives in legal filings and investor decks, not in approval announcements. Screening tools and AI investing tools can surface the headline instantly; they are considerably worse at flagging that the product behind the headline will not reach a shelf for another eighteen months. That distinction belongs in your own financial planning, not delegated to an alert.

The Bottom Line

Our read: Wezlana is a genuine milestone and a poor proxy for savings. Stelara ranked among the highest-grossing biologics in the world before competition arrived, which is exactly why its biosimilars became the closely watched test of whether faster approvals translate into money back in American pockets — and on balance, the 2023-to-2025 gap suggests the test is measuring the wrong stage of the pipeline. The more likely outcome over the next several years is that price relief tracks the number of launched entrants and the erosion of the interchangeability designation's exclusivity, not the pace of FDA sign-offs.

Disclaimer: This article is editorial commentary for informational purposes only. It does not constitute financial advice, medical advice, or a recommendation to buy or sell any security, and it does not reflect independent testing of any product. Decisions about biologic or biosimilar therapy should be made with a qualified healthcare professional. Research based on publicly available sources current as of September 8, 2026.